Lonza Group (LONN) Q1 2025 TU earnings summary

Executive summary

• Strong Q1 2025 performance across CDMO and all business segments, aligning with full-year expectations and confirming 2025 outlook for nearly 20% sales growth at constant exchange rates and core EBITDA margin approaching 30%.

• Robust commercial demand, high asset utilization, and healthy contract signings in early-stage business, with good visibility for 2025 demand.

• Capsules & Health Ingredients (CHI) business showed tangible recovery and positive momentum.

• Streamlined operating model implemented in April 2025, consolidating into three CDMO Business Platforms to support the new strategy.

• No material impact expected from tariffs or geopolitical developments due to global manufacturing footprint and hedging strategies.

Financial highlights

• Q1 2025 CDMO business on track for CER sales growth approaching 20% and core EBITDA margin near 30%.

• Excluding Vacaville, low-teens organic CER sales growth and margin improvement expected in CDMO business.

• Vacaville expected to contribute CHF 500 million in sales at a diluted core EBITDA margin.

• FY 2024 sales reached CHF 6.6 billion with CORE EBITDA of CHF 1.9 billion.

• CHI business expected to return to positive low- to mid-single-digit CER sales growth and core EBITDA margin in the mid-20s for 2025.

Outlook and guidance

• CDMO 2025 outlook confirmed: CER sales growth approaching 20%, core EBITDA margin approaching 30%.

• H2 2025 sales expected to exceed H1, but core EBITDA margin to be more balanced between halves due to strong H1 operational execution.

• No material financial impact expected from delayed equipment delivery for the Stein facility; operations now expected in 2027.

• Continued commitment to deliver full-year 2025 outlook, with strong contracting levels and early-stage interest.

• CHI business on track for historical growth and margin patterns, with mid-term guidance confirmed.